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348 The Journal of Thoracic and Cardbjective: If growth factor and cell-based therapy are to become therapeutic strategies,
better understanding of their physiologic effects in various patient populations will
eed to be gained. In this study, we examined age-dependent differences in vascular
ndothelial growth factor signaling before and after cardioplegia/cardiopulmonary
ypass.
ethods: Atrial tissue and peripheral blood of patients undergoing surgery were
xamined before and after cardioplegia/cardiopulmonary bypass. Patients were
ivided into younger (age  70) and older (age  70) groups. Coronary microvas-
ular responses, expression of vascular endothelial growth factor and its down-
tream signaling molecules, and the number of CD34 progenitor cells before and
fter cardioplegia/cardiopulmonary bypass were compared between groups.
esults: Advanced age was associated with impaired basal coronary microvas-
ular response to vascular endothelial growth factor (13%  5% at 1010
ol/L vascular endothelial growth factor; P  .04), whereas basal relaxation
esponse to substance P and sodium nitroprusside were similar between groups.
fter cardioplegia/cardiopulmonary bypass, the microvascular response to vas-
ular endothelial growth factor significantly worsened in both groups (both
 .05), and response to substance P (P  .05) was significantly impaired only
n older patients. Vascular endothelial growth factor expression increased after
ardioplegia/cardiopulmonary bypass in older (P  .01 vs before cardioplegia/
ardiopulmonary bypass), but not younger (P  .20) patients. Expression of
ther signaling molecules was unaffected by age or surgery. Circulating CD34
ells increased after cardioplegia/cardiopulmonary bypass in all patients but to
greater extent in younger patients (P  .01).
onclusions: The coronary microvascular response to vascular endothelial growth
actor is impaired in older patients. Combined with reduced progenitor cell mobilization,
hese results suggest new mechanisms for reduced angiogenic response in older patients.
rotein and gene therapy using growth factors and cell therapy using bone
marrow–derived stem cells are promising therapeutic strategies to induce
angiogenesis for ischemic heart disease in combination with conventional
evascularization techniques.1,2 Vascular endothelial growth factor (VEGF) has
een shown to be a potent angiogenic agent in swine models of chronic myocardial
schemia.3-5 However, clinical trials to date have not demonstrated the tremendous
ffects of angiogenesis shown in animal studies.6,7
Angiogenesis is induced in response to tissue injury. In this context, vasodila-
ation and mobilization of stem cell progenitors are important early events in the
ngiogenic process. VEGF plays an important role in coronary microvascular
asodilatation mediated through nitric oxide (NO).8 We9 have previously shown that
iovascular Surgery ● December 2006
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PO bioavailability in coronary microvessels is decreased after
ardioplegia and cardiopulmonary bypass (CP/CPB). Further-
ore, it has been shown that stem cell progenitors are mobi-
ized from bone marrow, resulting in elevation in their circu-
ating numbers after CP/CPB.10,11 These studies reinforce the
dea that exposure to CP/CPB can modulate important early
vents in angiogenesis with potential implications for growth
actor–based angiogenic therapy administered at the time of
urgical revascularization.
Advanced age remains an important risk factor for cor-
nary disease and has also been associated with reduced NO
vailability and endothelial dysfunction.12,13 Heiss and as-
ociates14 have demonstrated that flow-mediated dilatation
f the brachial artery in response to the NO-dependent
asodilator, acetylcholine, is impaired in older patients.
urthermore, the number of circulating endothelial progen-
tor cells is also reduced in the elderly.
The purposes of this study were (1) to evaluate age-
ependent differences in human coronary microvascular
esponse and to examine the expression of VEGF and its
ownstream mediators before and after CP/CPB and (2) to
nvestigate the effect of age on the mobilization of circulat-
ng CD34 stem progenitors after CP/CPB.
aterials and Methods
uman Tissue Samples
his study was approved by the Institutional Review Board of Beth
srael Deaconess Medical Center, Harvard Medical School. Informed
onsent was obtained from patients enrolled in the study as required
y the Institutional Review Board. Patients undergoing coronary
nd/or valvular surgery with CPB were enrolled. Samples of atrial
issue were harvested from the right atrial appendage before and after
P/CPB by a double purse-string technique as previously described. 15
he first specimen was taken at the time of atrial cannulation. The
econd specimen was collected by securing the second purse-string
uture below the cannulation site after weaning from CPB and at the
ime of decannulation. Tissue samples were immediately placed in
old (5°C-10°C) Krebs buffer solution for microvessel studies (n 
6) or frozen in liquid nitrogen and stored at80°C in preparation for
estern blotting (n  10). Because the median value of these 16
Abbreviations and Acronyms
CP  cardioplegia
CPB  cardiopulmonary bypass
eNOS  endothelial nitric oxide synthase
G-CSF  granulocyte-colony stimulating factor
NO  nitric oxide
NOS  nitric oxide synthase
PB  peripheral blood
SNP  sodium nitroprusside
VEGF  vascular endothelial growth factor
VEGFR2 vascular endothelial growth factor receptor 2amples was 69.5 years old, we divided the samples into older (age s
The Journal of Thoracic0) and younger (age  70) age groups. Peripheral blood samples
ere taken before skin incision (pre-CP/CPB) and 4 hours after
urgery (n  16). Blood was collected for flow cytometry analysis
nd measurement of serum levels of granulocyte-colony stimulating
actor (G-CSF).
Coronary microvessel studies. Microvessels (50-150 m in-
ernal diameters) were dissected from atrial tissue with a dissecting
icroscope (Olympus Optical, Tokyo, Japan) at original magnifi-
ations of 10 to 60. Microvessels were placed in a microvessel
hamber (University of Iowa Medical Instrumentation, Iowa City,
owa), cannulated with dual glass micropipettes, and secured with
0-0 nylon monofilament suture (Ethicon, Inc, Somerville, NJ).
rebs buffer solution, warmed to 37°C, was continuously circu-
ated through the microvessel chamber. The microvessels were
ressurized to 40 mm Hg in a no-flow state with a burette ma-
ometer filled with Krebs buffer solution. With an inverted micro-
cope (at original magnification 40 to 200; Olympus Optical,
okyo, Japan) connected to a video camera, the vessel image was
rojected onto a television monitor. An electronic dimension an-
lyzer (Living System Instrumentation, Burlington, Vt) was used
o measure internal lumen diameter, and measurements were re-
orded. After precontraction of microvessels by 30% to 50% of the
aseline diameter with the thromboxane A2 analog U46619 (0.1-
.0 mol/L), microvessel responses to VEGF165 (1015-1010 nmol/L)
ere examined. In addition, the response to sodium nitroprusside
SNP) (109-104 mol/L), an endothelium-independent cyclic
uanosine monophosphate-mediated vasodilator, and substance
(1014-107M), an endothelium-dependent vasodilator, was exam-
ned. Selected experiments were performed on vessels in the presence
f NO synthase (NOS) inhibitor, nitro-L-arginine (104 mol/L).
uman VEGF165 was purchased from R&D Systems (Minneapolis,
inn). SNP, nitro-L-arginine, U46619, and substance P were pur-
hased from Sigma Chemical Company (St Louis, Mo).
Western blot analysis. Whole-cell lysates were isolated from
he atrial tissue taken before and after CP/CPB (n  10) with a
IPA buffer (Boston Bioproducts, Worcester, Mass) and centri-
uged at 12,000g for 10 minutes at 4°C to separate soluble from
nsoluble fractions. The supernatant protein concentration was
easured spectrophotometrically at a 595-nm wave length. Total
rotein was fractionated by 4% to 20% gradient, sodium dodecyl-
ulfate polyacrylamide gel electrophoresis (Invitrogen, San Diego,
alif), and transferred to polyvinylidene difluoride membranes
Millipore, Bedford, Mass). The membranes were incubated over-
ight at 4°C using specific antibodies as follows, anti-VEGF
ntibody diluted to 1:250, anti-VEGF receptor 2 (VEGFR2) anti-
ody diluted to 1:200, anti-Akt antibody diluted to 1:1000 (Santa
ruz Biotechnology, Santa Cruz, Calif), phospho-Akt (Ser473)
ntibody diluted to 1:1000 (Cell Signaling Technology, Inc, Danvers,
ass), and anti-endothelial NOS (eNOS) antibody diluted to 1:2500
BD Bioscience, San Jose, Calif). Then, the membranes incubated for
hour in diluted appropriate secondary antibody (Jackson Immuno-
ab, West Grove, Pa). Immune complexes were visualized with the
nhanced chemiluminescence detection system (Amersham, Piscat-
way, NJ). Specific protein densities were measured by densitometric
uantification of autoradiograph films using NIH image J 1.33 (Na-
ional Institutes of Health, Bethesda, Md). Equal loading of various
amples was confirmed by Ponceau S staining.
and Cardiovascular Surgery ● Volume 132, Number 6 1349
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CSPFlow cytometry analysis. The sample of whole blood (100 L)
as stained with fluorescein isothiocyanate-conjugated anti-CD34
BD Bioscience, San Jose, Calif) monoclonal antibodies for
0 minutes at 4°C (n  16). Red blood cells and platelets were
ubsequently lysed for 15 minutes by an erythrocyte lysing buffer
Quiagen, Valencia, Calif), and the sample was centrifuged,
ashed twice, resuspended in phosphate-buffered saline solution,
nd analyzed by use of a FACS Caliber flow cytometer (Becton
ickinson, Franklin Lakes, NJ). Isotype-matched fluorescein
sothiocyanate-conjugated IgG1 antibodies (eBioscience) were
sed as controls. The number of CD34 cells was obtained as the
bsolute number in a total of 50,000 leukocytes. Leukocytes were
tained by 0.15% Trypan blue and counted using the lysed sample for
ow cytometry (FACS) without antibody. The number of CD34
ells in 100 L of peripheral blood (PB) was calculated as follows:
Total cells  Leukocytes (cells/L of PB)  100  (absolute
umber of CD34 cells)/50,000
nzyme-linked Immunosorbent Assay for G-CSF in
uman Plasma
lood was obtained from the patients before CPB and after CPB
n  16). Serum samples were obtained after centrifugation.
uantitative immunoassays of G-CSF were performed by a G-CSF
nzyme-linked immunosorbent assay kit (R&D Systems) accord-
ng to the maufacturer’s instructions.
ata Analysis
ll results are expressed as mean  SEM. Comparisons between
ge, VEGF concentration, and microvessel response were ana-
yzed by repeated-measures analysis of variance. Western blots
ere analyzed after digitalization of x-ray films using a flat-bed
canner (ScanJet 4c; Hewlett Packard, Palo Alto, Calif) and NIH
mage J 1.33 software (National Institutes of Health). Comparisons
f Pre-CP/CPB samples between younger and older groups were
nalyzed by unpaired 2-tailed t test and comparisons between
amples before and after CP/CPB were analyzed by paired 2-tailed
test. Statistical analyses were conducted with JMP 5.0 (SAS
nstitute Inc, Cary, NC) and Graph Pad Prism 4 (Graph Pad
oftware Inc, San Diego, Calif).
esults
atient characteristics are depicted in Table 1.
BLE 1. Patient characteristics
racteristic Total
. of patients 42
e (y) 68.2  1.7 (median 69.5)
nder (M/F) 29/13
pertension 33
percholesterolemia 28
betes 16
rgical procedure CABG 40; CABG  AVR 2
rtic crossclamp time (min) 70.8  4.6
al CPB time (min) 92.1  5.3BG, Coronary artery bypass grafting; AVR, aortic valve replacement; CPB, card
350 The Journal of Thoracic and Cardiovascular Surgery ● Decffects of Age on the Basal Coronary
icrovessel Response
he coronary microvascular relaxation response to VEGF
as diminished in older patients (P  0.04). The responses
o substance P (P  .68) and SNP (P  .59) were similar
etween the groups (Figure 1). After treatment of vessels with
04 mol/L of the NOS inhibitor nitro-L-arginine, the micro-
ascular responses to VEGF (1011 mol/L; 37.3% 16.5% vs
4.9%  8.4%; P  .02) and substance P (106 mol/L;
8.1%  12.2% vs 10.0%  6.5%; P  .01) were
ignificantly blunted. These results suggest that the re-
ponses to VEGF and substance P are, in large part, medi-
ted by NO release and that under basal conditions, ad-
anced age is associated with impaired VEGF signaling in
he coronary microcirculation.
yocardial Expression of VEGF and
elated Mediators
o further explore age-related differences in coronary mi-
rovascular response to VEGF, we evaluated the expression
f VEGF and its downstream mediators in older and
ounger patients using pre-CP/CPB samples. No significant
hanges were found in VEGF (P .30), VEGFR2 (P .59),
kt (P  .87), phospho-Akt (P .74), and eNOS (P  .72)
xpression between older and younger patients (Figure 2).
ifferential Coronary Microvascular Response
fter CP/CPB
he coronary microvascular response to VEGF was im-
aired after CP/CPB as compared with before CP/CPB in
oth older patients (P .01) and younger patients (P .02)
Figure 3, A and B). The coronary microvascular response to
NP was impaired after CP/CPB as compared with before
P/CPB in older patients (P .05) but was slightly increased
fter CP/CPB in younger patients (P  .03) (Figure 3, C and
). The coronary microvascular response to substance P
as significantly impaired after CP/CPB as compared with
efore CP/CPB in older patients (P  .01) and tended to
ecrease after CP/CPB in younger patients, but this trend
Patient age < 70 Patient age > 70
21 21
61.0  2.6 77.4  1.3
14/7 15/6
16 17
16 12
11 5
CABG 21 CABG 19; CABG  AVR 2
66.9  6.5 74.8  6.7
86.1  7.5 98.0  7.5A
ha
o
g
e
y
y
ia
u
o
otiopulmonary bypass grafting.
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Pid not reach statistical significance (P  .11) (Figure 3, E
nd F).
xpression of VEGF-Akt-eNOS Pathways
fter CP/CPB
n older patients, VEGF protein expression increased after
P/CPB compared with before CP/CPB (1.43-fold, P .01
igure 1. Plot of in vitro response of coronary microvascular
esponse to (A) VEGF (P  .04), (B) SNP (P  .68), and (C)
ubstance P (Sub P) (P  .59) using samples obtained before
P/CPB. Solid lines, Younger patients (age <70 years); dotted
ines, older patients (age > 70 years). Data are expressed as
ean  SEM. *P < .05 versus younger patients. VEGF, vascular
ndothelial growth factor; SNP, sodium nitroprusside; CP, cardio-
legia; CPB, cardiopulmonary bypass.s before CP/CPB). Protein expression of VEGFR2 (P  e
The Journal of Thoracic57 vs before CP/CPB), Akt (P  .78 vs before CP/CPB),
hospho-Akt (P  .39 vs before CP/CPB), and eNOS (P 
79 vs before CP/CPB) expression was similar in pre- and
ost-CP/CPB samples (Figure 4).
irculating CD34 Progenitor Cells
he number of circulating CD34 cells before CP/CPB was
imilar between younger and older patients (477.5  52.0
s 465.6 64.6 cells/100 L of PB, P 0.33). The number
f circulating CD34 cells increased significantly after CP/
PB in younger patients (190%, P  .01). Older patients
emonstrated a much smaller increase after CP/CPB, which
id not reach statistical significance (124%, P  .21). Se-
um levels of G-CSF increased similarly in younger (12.4
.7 vs 275.5 69.8 pg/mL, P .01) and older patients after
P/CPB (10.8  1.9 vs 360.0  77.0 pg/mL, P  .01)
Figure 5).
iscussion
n this study, we sought to determine the effects of aging on
igure 2. A, Protein expression of VEGF, VEGFR2, Akt, phospho-Akt,
nd eNOS in human atrial tissue before CP/CPB in patients younger
han 70 and older than 70 years analyzed by Western blotting. B,
uantitative analysis of protein expression of VEGF, VEGFR2, Akt,
hospho-Akt, and eNOS in human atrial tissue before CP/CPB in
atients younger than 70 and older than 70 years. p-Akt, Phospho-
kt; VEGF, vascular endothelial growth factor; VEGFR2, vascular
ndothelial growth factor receptor 2; ENOS, endothelial nitric oxide
ynthase; CP/CPB, cardioplegia/cardiopulmonary bypass.arly events important for angiogenesis in humans. The results
and Cardiovascular Surgery ● Volume 132, Number 6 1351
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CSPf this study demonstrate that VEGF-mediated coronary mi-
rovascular relaxation is diminished with advanced age. In
ddition, CP/CPB-induced impairments in coronary microvas-
ular function are accentuated in older patients. Furthermore,
obilization of CD34 stem cell progenitors is reduced after
P/CPB in older patients, despite maintained levels of G-CSF.
n summary, advanced age is associated with abnormalities in
mportant early events involved in angiogenesis.
Aging reduces basal and stimulated NO and has been as-
ociated with impaired peripheral and coronary endothelial
unction.8,12,13 NO-dependent, flow-mediated, and acetylcho-
ine-induced vasodilatation of the brachial artery is reduced in
lder individuals as compared with young, healthy volun-
eers.14,16 In this study, we found that coronary microvascular
elaxation in response to VEGF was impaired with advanced
ge. However, the response to substance P, which is mediated o
352 The Journal of Thoracic and Cardiovascular Surgery ● Dechrough tachykinin receptor leading to release of NO, was
imilar between groups. This suggests that older patients may
ave impaired VEGF signaling in the coronary microcircula-
ion whereas NO availability is unaffected under basal condi-
ions. In response to CP/CPB, coronary microvascular re-
ponse to VEGF was impaired significantly in all patients. The
esponse to substance P after CP/CPB, however, was reduced
ignificantly and to a greater extent in older patients, suggest-
ng that NO availability was more affected in response to
P/CPB in older patients.
Protein expression in the VEGF-Akt-eNOS signaling path-
ays was unchanged except for a slight increase in VEGF
rotein expression after CP/CPB in older patients. This is
onsistent with our previously published study, which showed
hat protein expression of VEGF is unchanged in patients with
Figure 3. Plot of in vitro response of
coronary microvascular response to
VEGF before and after CP/CPB in pa-
tients younger than 70 years (P  .02)
(A) and older than 70 years (P  .01)
(B). Plot of in vitro response of coro-
nary microvascular response to SNP
before and after CP/CPB in patients
younger than 70 years (P  .03) (C) and
older than 70 years (P .05) (D). Plot of
in vitro response of coronary microvas-
cular response to substance P (Sub P)
before and after CP/CPB in patients
younger than 70 years (P  .10) (E) and
older than 70 years (P  .046) (F). Data
are expressed as mean  SEM. *P <
.05 versus before CP/CPB. Solid lines,
Before CP/CPB; dotted lines, after CP/
CPB. (See Figures 1 and 2 for defini-
tions of abbreviations.)r without coronary artery disease despite differences in cor-
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Pnary microvascular response to VEGF.8 It is widely estab-
ished that downstream mediators of VEGF, like Akt and
NOS, are activated and inactivated on the basis of their
hosphorylation state.17 Furthermore, it has been demonstrated
hat expression of phospho-eNOS is reduced in the aortas of
igure 4. A, Change in protein expression of VEGF, VEGFR2, Akt,
hospho-Akt (p-Akt), and eNOS in human atrial tissue before and
fter CP/CPB between patients younger and older than 70 years
nalyzed by Western blotting. B, Quantitative analysis of the
rotein expression of VEGF, VEGFR2, Akt, phospho-Akt (p-Akt),
nd eNOS in human atrial tissue before CP/CPB between patients
ounger and older than 70 years. (See Figures 1 and 2 for defini-
ions of abbreviations.)The Journal of Thoracicged rats.18 In addition, the activity of eNOS is regulated by
ubcellular localization and/or protein-protein interactions. For
nstance, caveolin-1 plays an inhibitory role in eNOS activi-
y.19 Heat shock protein 90 interacts with eNOS activity by
kt.20 This accumulated evidence demonstrates that the con-
rol of VEGF signaling does not occur at the level of protein
xpression in the VEGF signaling pathway, but may occur at
he post-translational level in the human myocardium.
Mobilization of stem cell progenitors is an important
actor for tissue repair and angiogenesis that is affected by
xposure to the inflammatory stimulus of CP/CPB.10,11 Endo-
helial progenitors are defined as a lineage of cells expressing
D34 and VEGFR2 or AC133.10,21 Clinically, CD34 is used
s a marker of stem cells, and CD34 cell transplantation has
een shown to improve cardiac function in patients with heart
ailure.22 Recent studies have suggested that the number of
irculating endothelial progenitor cells is negatively correlated
ith age and that mobilization of endothelial progenitors is
educed in elderly patients and those with diabetes melli-
us.10,21 Furthermore, endothelial progenitor cells appear to
ave reduced functional activity in elderly patients.14 In our
tudy, the circulating number of CD34 cells increased signif-
cantly in response to CP/CPB by 90% in younger patients
fter CP/CPB, but only by 24% in older patients. G-CSF, a
otent stimulator for stem cell mobilization,23 increased to a
imilar extent in both younger and older patients, suggesting
hat this effect may be independent of G-CSF.
The results in this study provide us some perspective for
uture angiogenesis therapy in patients with end-stage coronary
isease, and particularly in the elderly. We demonstrated that
he coronary microvascular response to VEGF is decreased in
lder patients and that the response is also decreased after
P/CPB in both younger and older patients. Furthermore,
revious studies from our laboratory have indicated that the
ngiogenic response to exogenous VEGF is reduced in the
etting of hypercholesterolemic endothelial dysfunction.24
hese results suggest that impaired coronary microvascular
Figure 5. Change in circulating
CD34 cells after CP/CPB in patients
younger than 70 years (A) and older
than 70 years (B). CP/CPB, cardiople-
gia/cardiopulmonary bypass.and Cardiovascular Surgery ● Volume 132, Number 6 1353
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CSPesponse to VEGF, seen in older patients, may be associated
ith the limited development of angiogenesis in human clin-
cal trials.6 We have also focused on strategies to modulate the
ngiogenic response. For example, we have shown that sup-
lementation with L-arginine (an NO donor) is able to normal-
ze the impaired coronary microvascular response to VEGF as
ell as to improve the angiogenic response in a chronic isch-
mia model in hypercholesterolemic swine.25 On the other
and, supplementation with 3-hydroxy-3-methylglutaryl coen-
yme A reductase inhibitor, atorvastatin, improved endothelial
unction without improving the angiogenic response to
EGF.26 Therefore, these lines of evidence reinforce the crit-
cal role that the endothelium plays in the angiogenic response,
ut also demonstrate that in addition to endothelial function,
here are other factors that also modulate the angiogenic re-
ponse in vivo. Future strategies at therapeutic angiogenesis
hould therefore attempt to combat the various antiangiogenic
nfluences that exist in patients with end-stage coronary dis-
ase, particularly in the elderly.
imitations
ur experiments were performed on human atrial tissue
amples from patients with coronary artery disease who are
otential candidates for angiogenic therapy. Although there
re many similarities between atrial and ventricular myo-
ardium, important differences may also exist between the
wo, and the unavailability of human ventricular tissue
onstitutes a limitation of this study.27,28 In addition, limited
ample numbers precluded any subgroup analysis to evalu-
te the effects of various comorbidities such as diabetes and
ypercholesterolemia. Last, although CD34 is an accepted
arker for stem progenitors, other lineage makers as well as
he functional activity of stem cell progenitors should be
urther evaluated in future studies.
onclusions
dvanced age is associated with impaired VEGF signaling
s well as greater reductions in NO availability after CP/CPB.
urthermore, progenitor cell mobilization after CP/CPB is
iminished in older patients. These age-related differences
rovide new insights into the limited clinical benefits of
ngiogenic therapy in certain populations and may serve as
uture targets that can be modulated to enhance the effects
f angiogenic therapy in patients.
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iscussion
r Robert M. Mentzer (Detroit, Mich). Dr Mieno, I congratulate
ou and your colleagues on your efforts to help us better understand
he impact of aging on VEGF-stimulated angiogenesis. The magni-
ude of your work should not be underestimated. The use of a
reparation that allows one to assess the effect of various stimuli in the
resence and absence of VEGF on the microcirculation of human
trial tissue is quite innovative and represents a significant achieve-
ent in itself.
The first question I have for you relates to your findings in
egard to the intracellular signaling events. As you are aware, there
re numerous signaling molecules that have been associated with
EGF. I am curious to learn more about the rationale you used for
he selection of the molecules you elected to study, since there are
umerous other distant pathway signaling molecules that have
een implicated in VEGF-stimulated angiogenesis. These include
he mitogen-activated protein kinases, the p38 MAPK, phospho-
ipase C, and protein kinase C.
Dr Mieno. In this study, we looked at specific VEGFR2
ignaling pathways, because the VEGFR2 signaling pathway is
ore important for the development of angiogenesis than the
EGFR1 signaling pathways and other signaling pathways such as
rotein kinase C and those you have suggested. We have not
ooked at other signaling pathways.
Dr Mentzer. In regard to the experimental design, it would be
elpful if you would comment on the challenges and limitations of
tudying both aging and VEGF in the context of using CP/CPB.
ince this setting introduces a number of complex variables, is it
ikely that your findings reflect observations that are limited to this
etting? Would you also comment on some of the contributing
actors that might be considered unique to CP/CPB?
Dr Mieno. I think CP/CBP is important to induce ischemic or
xidative stress. Recent publications demonstrated that VEGF
ignaling is altered by ischemia and other kinds of stress. I think
P/CPB is one of the activators of VEGF signaling pathways.
It is easy to get human atrial tissue before and after CPB. And
P/CPB also induces ischemia or reperfusion injury in tissue. That
s why we are looking at difference in VEGF signaling pathway
efore and after CPB.
Dr Mentzer. Finally, I would like to hear your thoughts on
hy the results with VEGF in the surgical setting have been m
The Journal of Thoracicisappointing. Five years ago there was considerable enthusiasm
or VEGF therapy. At this very organization there were reports of
oth preclinical studies and phase I clinical trials that seemed to
ndicate a very promising role for this growth factor. The results
uggested improvement in ventricular function and, at the very
east, relief from disabling angina. As you pointed out in your first
lide, this no longer appears to be the case. On the basis of the
reclinical work presented today, what does the future hold for us
s it relates to VEGF gene therapy? What are your thoughts as to
here we should go from here?
Dr Mieno. As shown in this presentation, mobilization re-
ponse and coronary microvascular relaxation are important fac-
ors for development of angiogenesis. We demonstrated that events
uch as coronary microvascular relaxation and the progenitor mo-
ilization response were impaired by aging as well as after CPB.
his impaired response may be associated with limited develop-
ent of angiogenesis in human clinical trials using the VEGF
rotein. In the clinical setting, if we try to perform cell and protein
herapy, some additional treatment to improve the coronary micro-
ascular relaxation may be required in advance. Previously, we have
emonstrated that L-arginine supplementation, an NO donor, is able to
ormalize the impaired coronary microvascular response in ischemic
eft ventricular tissues of swine models of chronic ischemia.
Dr Sellke. Maybe I can add that there are some intrinsic problems
ith the myocardium in patients requiring angiogenic therapy. zHy-
ercholesterolemia, diabetes, oxidative stress, and other factors affect
he effectiveness of the angiogenic process. Protein growth factors do
ot work, nor does gene therapy work well in these patients. We have
o overcome these inhibitory factors before gene therapy or other
ypes of angiogenic therapy will become effective.
Dr Guo-Wei He (Hong Kong, China). There have been studies
howing that there are two subtypes of VEGF receptors, predom-
nantly on the vascular endothelial cell, KDR receptors (VEGFR2)
nd Flt receptors (VEGFR1). You have not used antagonists for
ither KDR or Flt receptors. Could you please comment on why
ou did not do it or whether you plan to do that.
Second, the diminished response of the microvascular circulation
o VEGF could be due to two reasons: (1) endothelial response
educed or (2) smooth muscle cell response reduced. Which one do
ou think is the factor in the patients with impaired VEGF response?
Dr Mieno. The first question is, as you suggested, that there are
wo major signaling pathways, VEGFR1 and VEGFR2, but we
ave not differentiated the specific signaling pathways in coronary
icrovascular relaxation.
Dr He. Is VEGFR2 related to KDR or related to Flt?
Dr Mieno. We have not used specific antibodies like VEGFR1
r VEGFR2, so I am not sure which pathway is predominantly
nvolved in the coronary microvascular relaxation to VEGF.
Dr He. My second question is, is it due to the diminished
esponse of the endothelial cell or smooth muscle cell?
Dr Mieno. The reduced coronary microvascular relaxation
s due to endothelial dysfunction as well as smooth muscle
ysfunction. I did not show the data for coronary microvascular
elaxation to SNP because of the time limitation, but we have
hose data. The coronary microvascular relaxation to SNP was
mpaired in older patients after CPB. This suggests smooth
uscle cell dysfunction.
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